U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection First Radiohybrid PSMA‐targeted PET Imaging Agent for Prostate Cancer

Written By PCRI
PCRI
Previous

Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
Next

Testosterone Replacement In Prostate Cancer Remission | Mark Scholz MD | Alex Scholz | PCRI